Longeveron Inc. operates as a clinical stage biotechnology company. The Company focuses on developing cellular therapies for specific aging-related and life-threatening conditions. Longeveron serves customers worldwide.

S-3 | Registration statement for specified transactions by certain issuers

Current Report (Form 8-K | Period ending 2025-03-13)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Longeveron (LGVN US)

S-3 | Registration statement for specified transactions by certain issuers

Current Report (Form 8-K | Period ending 2025-03-13)

Annual Report (Form 10-K | Period ending 2024-12-31)

Current Report (Form 8-K | Period ending 2025-01-27)

Current Report (Form 8-K | Period ending 2024-11-12)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)